The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Morphotek; Novartis; Pfizer
 
Imran Rafique
No Relationships to Disclose
 
Phu Tran
No Relationships to Disclose
 
William E. Gooding
No Relationships to Disclose
 
Liza Cosca Villaruz
Consulting or Advisory Role - Lilly
Research Funding - Lilly (Inst)
 
Timothy Francis Burns
No Relationships to Disclose
 
David Friedland
No Relationships to Disclose
 
Grace R. Tarabay
No Relationships to Disclose
 
Andrew D. Laman
No Relationships to Disclose
 
Dhaval R. Mehta
No Relationships to Disclose
 
Matthew Gerard Sulecki
No Relationships to Disclose
 
Daniel P. Petro
Consulting or Advisory Role - Celgene; Lilly
Speakers' Bureau - Boehringer Ingelheim; Celgene; Genentech
 
Mark S. Georgiadis
No Relationships to Disclose
 
Kevin M. Kane
No Relationships to Disclose
 
Sajid M. Peracha
No Relationships to Disclose
 
Kiran K. Rajasenan
Stock and Other Ownership Interests - CareCore; Mutual Funds; Pharmacyclics
 
Alexis Megaludis
No Relationships to Disclose
 
Lijun Dai
No Relationships to Disclose
 
Mark A. Socinski
Honoraria - Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
Research Funding - Genentech (Inst)